GILEAD SCIENCES, INC.

(GILD)
  Report
Real-time Estimate Cboe BZX  -  05/24 11:21:35 am EDT
63.56 USD   -0.16%
05/23WALL STREET STOCK EXCHANGE : Biden comments reassure investors
05/23SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target
MT
05/23ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société GILEAD SCIENCES, INC.
05/19Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Progr..
BU
05/17Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Car..
BU
05/17Gilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the ..
AQ
05/16FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention..
BU
05/05GILEAD SCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
05/04GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/02Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Kille..
BU
04/28GILEAD SCIENCES : View First Quarter 2022 Supplementary Info
PU
04/28GILEAD SCIENCES : ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS - Form 8-K
PU
04/28GILEAD SCIENCES : View First Quarter 2022 Summary of Remarks
PU
04/28GILEAD SCIENCES : View First Quarter 2022 Earnings Release
PU
04/28GILEAD : Q1 Earnings Snapshot
AQ
04/28Gilead Sciences Announces First Quarter 2022 Financial Results
BU
04/26Gilead Sciences to Present at Upcoming Investor Conferences
BU
04/26Gilead Sciences, Inc. - Veklury (Remdesivir) is First and Only Approved Treatment for P..
AQ
04/25Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under..
BU
04/25Several New Studies Presented at ECCMIC 2022 Confirm Veklury (Remdesivir) Activity in T..
AQ
04/24Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in ..
BU
04/22Gilead Statement on WHO Recommendation of Veklury (Remdesivir) and Acceleration of Preq..
AQ
04/21GILEAD SCIENCES : Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleratio..
PU
04/19Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturin..
BU
04/14Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, ..
BU
04/13FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
AQ
04/12Gilead Sciences, Inc. - FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studi..
AQ
04/11FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
BU
04/04Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment o..
AQ
04/01Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment ..
BU
03/28Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyo..
BU
03/24GILEAD SCIENCES : Annual Report Supplement - Corporate Information
PU
03/16Biopharma Stocks Targeting Crohn's Disease In $13.7 Billion Market (STAB, ARNA, GILD an..
AQ
03/15GILEAD SCIENCES : Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis ..
PU
03/11CAPITALGAINSREPORT : Biopharma Stocks Outperforming In $471 Billion Market (STAB, GILD, EX..
AQ
03/09GILEAD SCIENCES : to Expand Footprint in Oceanside
PU
03/07GILEAD SCIENCES : PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT OF PROGRESSION- FREE S..
PU
03/07Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-..
BU
03/07GILEAD SCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
03/02Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir ..
AQ
03/01Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir ..
BU
02/23GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
02/17Gilead Sciences, Inc. - New Clinical Data Support the Sustained Efficacy of Long-acting..
AQ
02/16New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's I..
BU
02/14Gilead Sciences, Inc. - Veklury (Remdesivir) Retains Antiviral Activity Against Omicron..
AQ
02/14Gilead Sciences, Inc. - Biktarvy Demonstrates High Efficacy and Durable Viral Suppressi..
AQ
02/14Gilead Sciences, Inc. - Phase 2/3 Interim Data Evaluating the Safety, Tolerability and ..
AQ
02/11GILEAD SCIENCES : View Q4 2021 Resource Book
PU
02/11Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Vek..
BU
02/11Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Tr..
BU
02/11Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emerg..
BU
02/10Takeda's Ramona Sequeira Becomes Board Chair of PhRMA
AQ
02/09Gilead Expands Availability of Veklury (remdesivir) to Non-Hospital Outpatient Faciliti..
AQ
02/09Gilead Sciences, Inc. to Help Dream Foundation Fulfill the Final Dreams of More Than 85..
AQ
02/08GILEAD SCIENCES : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient..
PU
02/08Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressin..
BU
02/04GILEAD SCIENCES : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient..
PU
02/03Gilead Sciences to Present at Upcoming Investor Conferences
BU
02/02Alphabet, Brinker International rise; PayPal, Gilead fall
AQ
02/02GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving li..
AQ
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Summary of Remarks
PU
02/01GILEAD : Q4 Earnings Snapshot
AQ
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Supplementary Info
PU
02/01GILEAD SCIENCES : Fourth Quarter 2021 Supplementary Info
PU
02/01GILEAD SCIENCES : ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS - Form 8-K
PU
02/01GILEAD SCIENCES : Announces Global Resolution of Bictegravir Patent Dispute with ViiV Heal..
PU
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Earnings Release
PU
02/01GILEAD SCIENCES : View Q4 & Full Year 2021 Presentation
PU
02/01Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
BU
02/01GILEAD SCIENCES INC : Results of Operations and Financial Condition (form 8-K)
AQ
02/01Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
BU
02/01U.s. fda approves new label update for car t-cell therapy yescarta showing prophylactic..
AQ
01/31U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylacti..
BU
01/31Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination..
AQ
01/25Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination..
BU
01/24Gilead Sciences-FDA Approves Veklury (Remdesivir) for the Treatment of Non-Hospitalized..
AQ
01/21FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at Hi..
BU
01/19GILEAD SCIENCES : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply..
PU
1  2  3  4  5  6  7  8  9  10Next
Official Publications
Upcoming event on GILEAD SCIENCES, INC.